Oncomed Pharma (OMED) Misses Q2 EPS by 50c

Oncomed Pharma (NASDAQ: OMED) reported Q2 EPS of ($0.53), $0.50 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $6 million versus the consensus estimate of $21.28 million.

For earnings history and earnings-related data on Oncomed Pharma (OMED) click here.

You May Also Be Interested In

• Okta upgraded as AI security opportunity boosts outlook
• Octave Intelligence plc (OCTV) Tops Q2 EPS by 4c ; Offers Guidance
• Clean Harbors to acquire EnviroServe for $470 million